SymBio Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYMQY research report →
Price Chart
About the company
SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. It researches, develops, manufactures, and sells new drugs focusing on the areas of oncology, hematology, and autoimmune diseases.
- CEO
- Fuminori Yoshida
- IPO
- 2016
- Employees
- 91
- HQ
- Tokyo, TY, JP
Get TickerSpark's AI analysis on SYMQY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $26.38M
- P/E
- -0.65
- PEG
- 0.55
- P/S
- 3.17
- P/B
- -8.51
- EV/EBITDA
- -0.57
- Div Yield
- 0.00%
- Gross Margin
- 70.02%
- Op Margin
- -523.59%
- Net Margin
- -532.90%
- ROE
- -936.82%
- ROIC
- -2325.51%
Latest fiscal year · YoY change
- Revenue
- $1.37B-44.1%
- Gross Profit
- $993.27M-47.0%
- Op Income
- $-4,655,968,416
- Net Income
- $-5,007,740,554-30.6%
- EPS
- $-99.73-18.6%
- OCF Growth
- -40.4%
- FCF Growth
- -38.5%
- 52W High
- $1.19
- 52W Low
- $0.56
- 50D MA
- $0.56
- 200D MA
- $0.58
- Beta
- 0.53
- RSI (14)
- 0
- Avg Volume
- 134
No earnings-call transcripts are available for SYMQY yet.
- Free Float
- 105.8%
- Shares Outstanding
- 47.28M
- Float Shares
- 50.00M
Our SYMQY coverage
Recent articles, reports, and earnings notes.
No research on SYMQY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SYMQY report →